Abeona Therapeutics Inc vs Avalanche Treasury Corporation Class A Common Stock — how do they compare? Abeona Therapeutics Inc trades at $7.57 (market cap $421.19M), while Avalanche Treasury Corporation Class A Common Stock trades at $0.34 (market cap $15.33M). The key difference: Abeona Therapeutics Inc is far larger — about 27.5× Avalanche Treasury Corporation Class A Common Stock's market cap, and Abeona Therapeutics Inc is trading nearer its 52-week high, Avalanche Treasury Corporation Class A Common Stock nearer its low. Which is the better fit depends on your goals.
| ABEO | AVAT | |
|---|---|---|
Market Cap | $421.19M | $15.33M |
Sector | Health | Financials |
52-Week High | $7.45 | $10.75 |
52-Week Low | $4.17 | $0.30 |
Enterprise Value | $276.10M | $15.33M |
Trailing returns across standard periods
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →Avalanche Treasury Corp operates as a digital asset treasury company focused on holding and managing digital asset investments. The company was founded on September 22, 2025, and is headquartered in New York, NY.
Read more on AVAT →